The management of atopic dermatitis is changing with the development of novel biological agents to target specific molecules in the inflammatory cascade. Dupilumab has proven its ability to act on the IL-4 receptor in treating atopic dermatitis. Thymic stromal lymphopoietin (TSLP) monoclonal antibody (AMG157/ MEDI9929) and OX40 blocking antibody (GBR 830) were developed by target the same pathway as dupilumab. The clinical data on the efficacy for these drugs is not yet known. There is some early evidence that AMG157/ MEDI9929 attenuates most measures of allergen-induced asthmatic responses. However, there is no public data on its ability to treat atopic dermatitis. In a Phase 2a study, GBR 830 showed at least a 50% reduction in patient’s Eczema Area and Severity Index (EASI) scores in 17 out of 23 patients, but it was not powered enough for statistical differences between GBR 830 versus placebo. Although there is potential for these two drugs to greatly improve the management of severe atopic dermatitis, there is not yet any available phase 3 clinical trials which are needed to truly evaluate their efficacy in affecting T-cells.

随着针对炎症级联反应中特定分子的新型生物制剂的发展，特应性皮炎的治疗正在发生变化。已证明Dupilumab在治疗特应性皮炎中具有作用于IL-4受体的能力。胸腺基质淋巴细胞生成素（TSLP）单克隆抗体（AMG157 / MEDI9929）和OX40阻断抗体（GBR 830）的靶向途径与dupilumab相同。这些药物功效的临床数据尚不清楚。早期有证据表明AMG157 / MEDI9929减弱了大多数变应原诱发的哮喘反应的措施。但是，尚无公开资料显示其治疗特应性皮炎的能力。在2a期研究中，GBR 830显示23名患者中的17名患者的湿疹面积和严重程度指数（EASI）得分至少降低了50％，但是它的功能不足以弥补GBR 830与安慰剂之间的统计差异。尽管这两种药物有可能大大改善严重异位性皮炎的治疗，但尚无任何可用于真正评估其影响T细胞功效的3期临床试验。